433 related articles for article (PubMed ID: 17525226)
1. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.
Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226
[TBL] [Abstract][Full Text] [Related]
2. Utility of optic pathway glioma screening in young children with neurofibromatosis type I: questions generated by a clinical audit.
Pilling RF; Lloyd IC; Huson S
Eye (Lond); 2010 Oct; 24(10):1603-5. PubMed ID: 20689568
[TBL] [Abstract][Full Text] [Related]
3. [Long-term outcome of gliomas of the visual pathway in type 1 neurofibromatosis].
Schröder S; Baumann-Schröder U; Hazim W; Haase W; Mautner VF
Klin Monbl Augenheilkd; 1999 Dec; 215(6):349-54. PubMed ID: 10637799
[TBL] [Abstract][Full Text] [Related]
4. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.
Thiagalingam S; Flaherty M; Billson F; North K
Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
6. Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?
Wolsey DH; Larson SA; Creel D; Hoffman R
J AAPOS; 2006 Aug; 10(4):307-11. PubMed ID: 16935228
[TBL] [Abstract][Full Text] [Related]
7. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.
Levin MH; Armstrong GT; Broad JH; Zimmerman R; Bilaniuk LT; Feygin T; Li Y; Liu GT; Fisher MJ
Br J Ophthalmol; 2016 Apr; 100(4):510-4. PubMed ID: 26294105
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1.
Kuenzle C; Weissert M; Roulet E; Bode H; Schefer S; Huisman T; Landau K; Boltshauser E
Neuropediatrics; 1994 Dec; 25(6):295-300. PubMed ID: 7770126
[TBL] [Abstract][Full Text] [Related]
9. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
10. The technique, validity and clinical use of the sweep VEP.
Almoqbel F; Leat SJ; Irving E
Ophthalmic Physiol Opt; 2008 Sep; 28(5):393-403. PubMed ID: 18761477
[TBL] [Abstract][Full Text] [Related]
11. Optic radiation involvement in optic pathway gliomas in neurofibromatosis.
Liu GT; Brodsky MC; Phillips PC; Belasco J; Janss A; Golden JC; Bilaniuk LL; Burson GT; Duhaime AC; Sutton LN
Am J Ophthalmol; 2004 Mar; 137(3):407-14. PubMed ID: 15013861
[TBL] [Abstract][Full Text] [Related]
12. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.
Campagna M; Opocher E; Viscardi E; Calderone M; Severino SM; Cermakova I; Perilongo G
Pediatr Blood Cancer; 2010 Dec; 55(6):1083-8. PubMed ID: 20979170
[TBL] [Abstract][Full Text] [Related]
13. Intracranial visual pathway gliomas in children with neurofibromatosis.
Packer RJ; Bilaniuk LT; Cohen BH; Braffman BH; Obringer AC; Zimmerman RA; Siegel KR; Sutton LN; Savino PJ; Zackai EH
Neurofibromatosis; 1988; 1(4):212-22. PubMed ID: 3152473
[TBL] [Abstract][Full Text] [Related]
14. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.
Sharif S; Ferner R; Birch JM; Gillespie JE; Gattamaneni HR; Baser ME; Evans DG
J Clin Oncol; 2006 Jun; 24(16):2570-5. PubMed ID: 16735710
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pattern visual-evoked potentials to perimetry in the detection of visual loss in children with optic pathway gliomas.
Kelly JP; Weiss AH
J AAPOS; 2006 Aug; 10(4):298-306. PubMed ID: 16935227
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of systematic brain magnetic resonance imaging in children with neurofibromatosis type 1].
Blanchard G; Pinson S; Rousselle C; Lorthois S; Combemale P; Bernard M; Lion Francois L
Arch Pediatr; 2009 Dec; 16(12):1527-32. PubMed ID: 19864117
[TBL] [Abstract][Full Text] [Related]
17. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.
Wan MJ; Ullrich NJ; Manley PE; Kieran MW; Goumnerova LC; Heidary G
J Neurooncol; 2016 Aug; 129(1):173-8. PubMed ID: 27311725
[TBL] [Abstract][Full Text] [Related]
18. Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.
Hepokur M; Sarici AM
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1757-1765. PubMed ID: 29754292
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis type 1 and optic pathway glioma. A long-term follow-up.
Lama G; Esposito Salsano M; Grassia C; Calabrese E; Grassia MG; Bismuto R; Melone MA; Russo S; Scuotto A
Minerva Pediatr; 2007 Feb; 59(1):13-21. PubMed ID: 17301720
[TBL] [Abstract][Full Text] [Related]
20. Visual loss in orbitofacial neurofibromatosis type 1.
Oystreck DT; Morales J; Chaudhry I; Alorainy IA; Elkhamary SM; Pasha TM; Bosley TM
Ophthalmology; 2012 Oct; 119(10):2168-73. PubMed ID: 22709421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
